Baird Medical Investment Holdings Limited (BDMD) Key Metrics
BDMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $18.2M
- Enterprise value
- $39.2M
- P/E (TTM)
- —
- Forward P/E
- 5.6
- PEG ratio
- —
- Price / sales
- 0.7
- Price / book
- 0.7
- EV / EBITDA
- 133.6
- Dividend yield
- —
- Beta
- −1.12
BDMD key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBDMD valuation Price multiples at each fiscal year-end price.
Price / sales−68.1%
1.7
2025 · hover or tap a bar for each year
20192025
Price / book−75.5%
1.2
2025 · hover or tap a bar for each year
20192025
Free cash flow yield+1.0 pts
−3.7%
2025 · hover or tap a bar for each year
20192025
BDMD returns How much profit the business earns on the capital it uses.
Return on equity−109.8 pts
−76.8%
2025 · hover or tap a bar for each year
20192025
Return on invested capital−64.3 pts
−37.3%
2025 · hover or tap a bar for each year
20192025
Return on assets−55.4 pts
−36.9%
2025 · hover or tap a bar for each year
20192025
Free cash flow margin+18.6 pts
−6.2%
2025 · hover or tap a bar for each year
20192025
Asset turnover−44.5%
0.31
2025 · hover or tap a bar for each year
20192025
BDMD per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−43.9%
$0.81
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.98
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$0.05
2025 · hover or tap a bar for each year
20192025
Book value per share−27.1%
$1.13
2025 · hover or tap a bar for each year
20192025
Shares outstanding+8.4%
27.8M
2025 · hover or tap a bar for each year
20192025
BDMD financial health Debt, liquidity and how easily interest is covered.
Debt / equity+16.9%
0.62
2025 · hover or tap a bar for each year
20192025
Net debt+$1.2M
$19.1M
2025 · hover or tap a bar for each year
20192025
Current ratio−4.2%
1.70
2025 · hover or tap a bar for each year
20192025
Interest coverage
-34.6
2025 · hover or tap a bar for each year
20192025
Debt / assets+3.4%
0.28
2025 · hover or tap a bar for each year
20192025
BDMD efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+337 days
722 days
2025 · hover or tap a bar for each year
20192025
Days of inventory+17 days
119 days
2025 · hover or tap a bar for each year
20192025
Days payables outstanding+78 days
153 days
2025 · hover or tap a bar for each year
20192025
Cash conversion cycle+277 days
688 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue−7.5 pts
0.2%
2025 · hover or tap a bar for each year
20192025
BDMD valuation history
Fiscal year-endToday7-year median
BDMD returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BDMD debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BDMD cash returned to shareholders
DividendsBuybacksFree cash flow
BDMD price vs earnings per share
Share price at year-endEPS (right axis)
BDMD key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $37.8M | $194.8M | — | — | — | — | — |
| Enterprise value | $56.9M | $212.7M | — | — | — | — | — |
| P/E ratio | — | 15.6 | — | — | — | — | — |
| Price / sales | 1.7 | 5.3 | — | — | — | — | — |
| Price / book | 1.2 | 4.9 | — | — | — | — | — |
| EV / sales | 2.5 | 5.7 | — | — | — | — | — |
| EV / EBITDA | — | 13.2 | — | — | — | — | — |
| Earnings yield | −72.2% | 6.4% | — | — | — | — | — |
| Free cash flow yield | −3.7% | −4.7% | — | — | — | — | — |
| Share price at fiscal year-end | $1.36 | $7.60 | — | — | — | — | — |
| Per share | |||||||
| Revenue per share | $0.81 | $1.45 | $4.15 | $4.88 | $3.86 | $2.52 | $1.70 |
| Earnings per share | −$0.98 | $0.49 | $1.39 | $1.75 | $1.62 | $0.99 | −$1.00 |
| Operating cash flow per share | −$0.05 | −$0.25 | −$0.13 | $0.07 | $0.73 | $0.54 | $0.61 |
| Free cash flow per share | −$0.05 | −$0.36 | −$0.48 | −$0.76 | $0.54 | $0.45 | $0.48 |
| Cash per share | $0.01 | $0.12 | $0.22 | $0.27 | $0.48 | $0.16 | $0.04 |
| Book value per share | $1.13 | $1.55 | $4.71 | $3.61 | $0.72 | $1.00 | −$3.05 |
| Tangible book value per share | $1.13 | $1.54 | $4.70 | $3.59 | $0.71 | $0.98 | −$3.07 |
| Dividends per share | — | — | — | $0.00 | $0.75 | — | — |
| Capex per share | $0.00 | $0.11 | $0.35 | $0.83 | $0.19 | $0.09 | $0.14 |
| Debt per share | $0.69 | $0.81 | $1.31 | $1.04 | $0.41 | $0.56 | $4.03 |
| Shares outstanding | 27.8M | 25.6M | 7.6M | 7.2M | 7.2M | 7.2M | 7.2M |
| Change in shares outstanding | +8.4% | +237.9% | +5.5% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −76.8% | 33.0% | 34.2% | 80.7% | 188.1% | — | — |
| Return on invested capital (ROIC) | −37.3% | 27.0% | 27.1% | 66.3% | 129.9% | 87.1% | 65.3% |
| Return on assets (ROA) | −36.9% | 18.5% | 21.2% | 36.6% | 54.1% | 49.3% | −61.1% |
| Return on tangible assets | −39.2% | 16.0% | 18.6% | 29.6% | 44.9% | 42.1% | −62.2% |
| Free cash flow margin | −6.2% | −24.8% | −11.6% | −15.6% | 14.0% | 17.9% | 28.1% |
| Income quality (OCF / net income) | — | −0.51 | −0.10 | 0.04 | 0.45 | 0.55 | — |
| Financial health | |||||||
| Total debt | $19.3M | $20.9M | $9.9M | $7.4M | $2.9M | $4.1M | $28.9M |
| Cash & short-term investments | $178,321 | $3.0M | $1.6M | $1.9M | $3.4M | $1.1M | $257,076 |
| Net debt | $19.1M | $17.9M | $8.3M | $5.5M | −$505,103 | $2.9M | $28.7M |
| Debt / equity | 0.62 | 0.53 | 0.28 | 0.29 | 0.56 | 0.56 | — |
| Debt / assets | 0.28 | 0.27 | 0.17 | 0.17 | 0.11 | 0.24 | 2.46 |
| Net debt / EBITDA | — | 1.11 | 0.62 | 0.34 | −0.04 | 0.28 | 4.91 |
| Current ratio | 1.70 | 1.77 | 2.11 | 2.11 | 2.29 | 1.41 | 0.26 |
| Quick ratio | 1.66 | 1.74 | 2.05 | 2.03 | 1.98 | 1.32 | 0.24 |
| Interest coverage | -34.6 | 26.6 | 41.7 | 45.6 | 77.4 | 61.8 | 62.6 |
| Working capital | $22.6M | $26.8M | $21.1M | $17.7M | $12.6M | $3.8M | −$24.9M |
| Invested capital | $50.5M | $57.6M | $44.0M | $31.5M | $4.7M | $10.1M | $6.8M |
| Tangible asset value | $31.2M | $39.7M | $35.6M | $25.7M | $15.7M | $6.6M | −$22.8M |
| Net current asset value | $16.5M | $23.2M | $19.1M | $16.9M | $12.1M | $2.8M | −$25.7M |
| Graham number | — | $4.11 | $12.14 | $11.91 | $5.14 | $4.72 | — |
| Graham net-net per share | −$0.21 | $0.01 | $0.64 | $0.60 | $0.56 | −$0.35 | −$4.22 |
| Capital allocation | |||||||
| Dividends paid | — | — | — | $0 | $5.4M | — | — |
| Dividend payout ratio | — | — | — | 0.0% | 46.5% | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | 140.3% | — | — |
| Capex / revenue | 0.2% | 7.7% | 8.4% | 17.0% | 5.0% | 3.6% | 8.1% |
| Capex / operating cash flow | — | — | — | 1,225.2% | 26.4% | 16.8% | 22.3% |
| Capex / depreciation | 0.04 | 1.89 | 1.91 | 4.05 | 0.99 | 0.61 | 1.54 |
| Stock-based compensation / revenue | 77.5% | 0.0% | 0.0% | — | — | — | — |
| R&D / revenue | 89.3% | 16.7% | 13.6% | 11.0% | 3.8% | 4.1% | 9.5% |
| SG&A / revenue | 108.2% | 26.9% | 35.3% | 19.8% | 24.0% | 27.6% | 32.7% |
| Efficiency | |||||||
| Days sales outstanding | 721.6 | 384.7 | 326.4 | 193.5 | 136.1 | 128.8 | 136.3 |
| Days of inventory on hand | 119.0 | 101.6 | 105.2 | 112.5 | 155.3 | 110.4 | 199.4 |
| Days payables outstanding | 152.7 | 75.1 | 33.1 | 14.4 | 16.1 | 11.7 | 28.2 |
| Cash conversion cycle (days) | 687.9 | 411.2 | 398.5 | 291.6 | 275.3 | 227.5 | 307.5 |
| Receivables turnover | 0.51 | 0.95 | 1.12 | 1.89 | 2.68 | 2.83 | 2.68 |
| Payables turnover | 2.39 | 4.86 | 11.04 | 25.37 | 22.65 | 31.12 | 12.95 |
| Inventory turnover | 3.07 | 3.59 | 3.47 | 3.24 | 2.35 | 3.30 | 1.83 |
| Asset turnover | 0.31 | 0.55 | 0.63 | 1.02 | 1.29 | 1.26 | 1.04 |
| Average receivables | $44.6M | $39.0M | $28.1M | $18.6M | $10.3M | $6.4M | $4.6M |
| Average payables | $1.5M | $901,428 | $383,026 | $278,038 | $200,668 | $80,684 | $100,245 |
| Average inventory | $1.2M | $1.2M | $1.2M | $2.2M | $1.9M | $759,774 | $709,474 |
| Intangibles / total assets | 0.1% | 0.1% | 0.1% | 0.3% | 0.5% | 1.0% | 1.7% |
Computed from BDMD's annual financial statements (latest annual report filed April 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BDMD valuation and financial ratios
Baird Medical Investment earned a return on equity of −76.8% and a return on invested capital of −37.3% in fiscal 2025. It ended the year with $19.3 million of debt and $0.2 million in cash and short-term investments, net debt of $19.1 million. The share count rose 286.7% from 7.2M to 27.8M over 6 years.
See the BDMD income statement, the BDMD chart for price history, or the BDMD stock overview for the latest quote and news.
BDMD key metrics FAQ
What is Baird Medical Investment's return on equity?
Baird Medical Investment's return on equity (ROE) was −76.8% in fiscal 2025: net income of -$27.3 million on average shareholders' equity of $35.5 million.
What is Baird Medical Investment's ROIC?
Baird Medical Investment's return on invested capital was −37.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Baird Medical Investment have?
Baird Medical Investment had total debt of $19.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.62.
What is Baird Medical Investment's free cash flow yield?
Baird Medical Investment generated -$1.4 million of free cash flow in fiscal 2025, a free cash flow yield of −3.7% on its market value at year-end ($37.8 million).
What is Baird Medical Investment's current ratio?
Baird Medical Investment's current ratio was 1.70 at the end of fiscal 2025: current assets were 1.70 times current liabilities.